TickerFacts.

Charles River Laboratories International, Inc. (CRL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$428.47M
Year ended 2025-12-27
$388.03M
Trailing 12 months to 2026-06-27
-23.4%
3-year compound annual growth
-8.5%
5-year compound annual growth
+3.6%
10-year compound annual growth
$954.85M2008-12-27: -$364.99M2009-12-26: $259.57M2010-12-25: -$204.86M2011-12-31: $259.54M2012-12-29: $247.04M2013-12-28: $248.04M2014-12-27: $274.12M2015-12-26: $301.33M2016-12-31: $364.21M2017-12-30: $419.44M2018-12-29: $493.16M2019-12-28: $549.25M2020-12-26: $667.65M2021-12-25: $855.40M2022-12-31: $954.85M2023-12-30: $931.38M2024-12-28: $589.09M2025-12-27: $428.47M$428.47M
2008-12-27 EBITDA (USD) 2025-12-27
Period endedEBITDAChange YoYSource filing
2025-12-27$428.47M-27.3%2026-02-18, From 2024-12-29
2024-12-28$589.09M-36.8%2026-02-18, From 2023-12-31
2023-12-30$931.38M-2.5%2026-02-18, From 2023-01-01
2022-12-31$954.85M+11.6%2025-02-19, From 2021-12-26
2021-12-25$855.40M+28.1%2024-02-14, From 2020-12-27
2020-12-26$667.65M+21.6%2023-02-22, From 2019-12-29
2019-12-28$549.25M+11.4%2022-02-16, From 2018-12-30
2018-12-29$493.16M+17.6%2021-02-17, From 2017-12-31
2017-12-30$419.44M+15.2%2020-02-11, From 2017-01-01
2016-12-31$364.21M+20.9%2019-02-13, From 2015-12-27
2015-12-26$301.33M+9.9%2018-02-13, From 2014-12-28
2014-12-27$274.12M+10.5%2017-02-14, From 2013-12-29
2013-12-28$248.04M+0.4%2016-02-12, From 2012-12-30
2012-12-29$247.04M-4.8%2015-02-17, From 2012-01-01
2011-12-31$259.54Mn/m2014-02-25, From 2010-12-26
2010-12-25-$204.86Mn/m2013-02-27, From 2009-12-27
2009-12-26$259.57Mn/m2012-02-27, From 2008-12-28
2008-12-27-$364.99Mn/a2011-02-23, From 2007-12-30

EBITDA at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Charles River Laboratories International, Inc. (CRL)2025-12-27$428.47M-27.3%
Incyte Corp (INCY)2025-12-31$1.61B+967.7%
Icon PLC (ICLR)2025-12-31$825.84M-45.7%
Iqvia Holdings Inc. (IQV)2025-12-31$3.33B+0.3%
NRC Health (NRC)2025-12-31$30.21M-26.7%
MaxCyte, Inc. (MXCT)2025-12-31-$47.56Mn/m
OmniAb, Inc. (OABI)2025-12-31-$47.22Mn/m
Foxo Technologies Inc. (FOXO)2025-12-31-$9.73Mn/m
bioAffinity Technologies, Inc. (BIAF)2025-12-31-$10.07Mn/m

Compare CRL, INCY, ICLR, IQV side by side · Screen every company in Services-Commercial Physical & Biological Research ↗